BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, Sundar R, Soon YY. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632. [PMID: 35236664 DOI: 10.1136/bmj-2021-068632] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 63.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Bu F, Li L, Zhang X, Yan J, Huang T. COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews. Front Public Health 2022;10. [DOI: 10.3389/fpubh.2022.1072137] [Reference Citation Analysis]
2 Beale S, Burns R, Braithwaite I, Byrne T, Lam Erica Fong W, Fragaszy E, Geismar C, Hoskins S, Kovar J, Navaratnam AM, Nguyen V, Patel P, Yavlinsky A, Van Tongeren M, Aldridge RW, Hayward A. Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.10.080] [Reference Citation Analysis]
3 Kim J, Seo H, Kim H, Kim D, Kwon H, Kim Y. Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. Viruses 2022;14:2458. [DOI: 10.3390/v14112458] [Reference Citation Analysis]
4 Brandstetter C, Haller MC, Berger JM, Kerschner H, Apfalter P, Cejka D. Humoral response after a third and fourth dose of mRNA-based SARS-CoV-2 vaccine in previously seronegative kidney transplant recipients. Wien Klin Wochenschr 2022. [PMID: 36326920 DOI: 10.1007/s00508-022-02103-1] [Reference Citation Analysis]
5 Wang Y, Zhu Q, Sun R, Yi X, Huang L, Hu Y, Ge W, Gao H, Ye X, Song Y, Shao L, Li Y, Li J, Guo T, Shi J. Longitudinal proteomic investigation of COVID-19 vaccination.. [DOI: 10.1101/2022.11.01.22281744] [Reference Citation Analysis]
6 Kim YY, Choe YJ, Kim J, Kim RK, Jang EJ, Park SK, Lim DS, Yi S, Lee S, Kwon GY, Shin JY, Choi SY, Jeong MJ, Park YJ. Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents. Emerg Infect Dis 2022;28:2165-70. [PMID: 36191615 DOI: 10.3201/eid2811.220918] [Reference Citation Analysis]
7 Czarnecka K, Czarnecka P, Tronina O, Durlik M. Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience. JCM 2022;11:6464. [DOI: 10.3390/jcm11216464] [Reference Citation Analysis]
8 Najjar-Debbiny R, Gronich N, Weber G, Stein N, Saliba W. Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis. Clin Infect Dis 2022. [PMID: 36310534 DOI: 10.1093/cid/ciac855] [Reference Citation Analysis]
9 Dainese C, Valeri F, Bardetta M, Sella C, Porreca A, Valpreda A, Pittaluga F, Mengozzi G, Bruno B, Borchiellini A. Impact of COVID-19 Infection, Vaccination, and Serological Response in Immune Thrombocytopenic Purpura Patients: A Single-Center Global Analysis. Biomedicines 2022;10:2674. [DOI: 10.3390/biomedicines10112674] [Reference Citation Analysis]
10 Scaglione V, Rotundo S, Marascio N, De Marco C, Lionello R, Veneziano C, Berardelli L, Quirino A, Olivadese V, Serapide F, Tassone B, Morrone HL, Davoli C, La Gamba V, Bruni A, Cesana BM, Matera G, Russo A, Costanzo FS, Viglietto G, Trecarichi EM, Torti C; IDTM U. M. G. COVID-19 Group. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis 2022;22:793. [PMID: 36266619 DOI: 10.1186/s12879-022-07774-9] [Reference Citation Analysis]
11 Loubet P, Wittkop L, Ninove L, Chalouni M, Barrou B, Blay JY, Hourmant M, Thouvenot E, Laville M, Laviolle B, Lelievre JD, Morel J, Quoc SN, Spano JP, Terrier B, Thiebaut A, Viallard JF, Vrtovsnik F, Circosta S, Esterle L, Levier A, Vanhems P, Tartour E, Parfait B, de Lamballerie X, Launay O; ANRS0001S COV-POPART study group. One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort. Clin Microbiol Infect 2022:S1198-743X(22)00522-5. [PMID: 36252789 DOI: 10.1016/j.cmi.2022.10.009] [Reference Citation Analysis]
12 Pinto-Álvarez M, Fernández-Niño JA, Arregocés-Castillo L, Rojas-Botero ML, Palacios AF, Galvis-Pedraza M, Ruiz-Gomez F. Real-world Evidence of COVID-19 Vaccines Effectiveness in Solid-organ Transplant Recipient Population in Colombia: A Study Nested in the Esperanza Cohort. Transplantation 2022. [PMID: 36228269 DOI: 10.1097/TP.0000000000004411] [Reference Citation Analysis]
13 Raptis CE, Berger CT, Ciurea A, Andrey DO, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Front Immunol 2022;13:1016927. [DOI: 10.3389/fimmu.2022.1016927] [Reference Citation Analysis]
14 Müller L, Andrée M, Moskorz W, Drexler I, Hauka S, Ptok J, Walotka L, Grothmann R, Hillebrandt J, Ritchie A, Peter L, Walker A, Timm J, Adams O, Schaal H. Adjusted COVID-19 booster schedules balance age-dependent differences in antibody titers benefitting risk populations. Front Aging 2022;3:1027885. [PMID: 36313184 DOI: 10.3389/fragi.2022.1027885] [Reference Citation Analysis]
15 Al Hajji Y, Taylor H, Starkey T, Lee LYW, Tilby M. Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. Br J Cancer 2022. [PMID: 36224402 DOI: 10.1038/s41416-022-01951-y] [Reference Citation Analysis]
16 Ustianowski A. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. Expert Rev Anti Infect Ther 2022. [PMID: 36217836 DOI: 10.1080/14787210.2022.2134118] [Reference Citation Analysis]
17 Banjongjit A, Phirom S, Phannajit J, Jantarabenjakul W, Paitoonpong L, Kittanamongkolchai W, Wattanatorn S, Prasithsirikul W, Eiam-Ong S, Avihingsanon Y, Hansasuta P, Vanichanan J, Townamchai N. Benefits of Switching Mycophenolic Acid to Sirolimus on Serological Response after a SARS-CoV-2 Booster Dose among Kidney Transplant Recipients: A Pilot Study. Vaccines (Basel) 2022;10:1685. [PMID: 36298550 DOI: 10.3390/vaccines10101685] [Reference Citation Analysis]
18 Berber E, Sumbria D, Kokkaya S. A metabolic blueprint of COVID-19 and long-term vaccine efficacy. Drug Metabolism and Personalized Therapy 2022;0. [DOI: 10.1515/dmpt-2022-0148] [Reference Citation Analysis]
19 Yin J, Chen Y, Li Y, Zhang X, Wang C. Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis. Hum Vaccin Immunother 2022;:2119763. [PMID: 36161976 DOI: 10.1080/21645515.2022.2119763] [Reference Citation Analysis]
20 Scurr MJ, Lippiatt G, Capitani L, Bentley K, Lauder SN, Smart K, Somerville MS, Rees T, Stanton RJ, Gallimore A, Hindley JP, Godkin A. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nat Commun 2022;13:5422. [PMID: 36130936 DOI: 10.1038/s41467-022-32985-8] [Reference Citation Analysis]
21 Kang L, Shang W, Gao P, Wang Y, Liu J, Liu M. Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2022;10:1569. [PMID: 36146647 DOI: 10.3390/vaccines10091569] [Reference Citation Analysis]
22 Hederman AP, Natarajan H, Wiener JA, Wright PF, Bloch EM, Tobian AA, Redd AD, Blankson JN, Rottenstreich A, Zarbiv G, Wolf D, Goetghebuer T, Marchant A, Ackerman ME. SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations.. [DOI: 10.1101/2022.09.15.22280000] [Reference Citation Analysis]
23 Dogra P, Schiavone C, Wang Z, Ramírez JR, Caserta S, Staquicini DI, Markosian C, Wang J, Sostman HD, Pasqualini R, Arap W, Cristini V. Mathematical modeling identifies optimal dosing schedules for COVID-19 vaccines to minimize breakthrough infections.. [DOI: 10.1101/2022.09.14.22279959] [Reference Citation Analysis]
24 Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JP, Chiang HL, Sun CP, Lee IJ, Li WS, Hsieh HP, Tao MH, Wu HC. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci 2022;29:68. [PMID: 36096815 DOI: 10.1186/s12929-022-00852-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Cheng MM, Reyes C, Satram S, Birch H, Gibbons DC, Drysdale M, Bell CF, Suyundikov A, Ding X, Maher MC, Yeh W, Telenti A, Corey L. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United States.. [DOI: 10.1101/2022.09.07.22279497] [Reference Citation Analysis]
26 Damerau L, Mühlenbruch G, Evenschor-Ascheid A, Fussen C, Nienhaus A, Terschüren C, Herold R, Harth V. Coronavirus Vaccination: Spike Antibody Levels in Health Workers after Six Months-A Cross-Sectional Study. Int J Environ Res Public Health 2022;19:11422. [PMID: 36141696 DOI: 10.3390/ijerph191811422] [Reference Citation Analysis]
27 Cheung MW, Dayam RM, Law JC, Goetgebuer RL, Chao GYC, Finkelstein N, Stempak JM, Pereira D, Croitoru D, Acheampong L, Rizwan S, Lee JD, Ganatra D, Law R, Delgado-brand M, Mailhot G, Piguet V, Silverberg MS, Watts TH, Gingras A, Chandran V. Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases. RMD Open 2022;8:e002622. [DOI: 10.1136/rmdopen-2022-002622] [Reference Citation Analysis]
28 Peghin M, Graziano E, Grossi PA. SARS-CoV-2 Vaccination in Solid-Organ Transplant Recipients. Vaccines 2022;10:1430. [DOI: 10.3390/vaccines10091430] [Reference Citation Analysis]
29 Bain N, Nguyen M, Grech L, Day D, Mccartney A, Webber K, Kwok A, Harris S, Chau H, Chan B, Nott L, Hamad N, Tognela A, Underhill C, Loe BS, Freeman D, Segelov E; on behalf of the CANVACCS Investigators. COVID-19 Vaccine Hesitancy in Australian Patients with Solid Organ Cancers. Vaccines 2022;10:1373. [DOI: 10.3390/vaccines10091373] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Wiedemann A, Pellaton C, Dekeyser M, Guillaumat L, Déchenaud M, Krief C, Lacabaratz C, Grimbert P, Pantaleo G, Lévy Y, Durrbach A. Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients. Front Med 2022;9. [DOI: 10.3389/fmed.2022.978764] [Reference Citation Analysis]
31 Toapanta-Yanchapaxi L, Chiquete E, Ávila-Rojo E, López-Yánez S, Luna Del Villar Velasco S, Rivera Monroy S, López Gómez T, Andrés Aguilar JB, Balcázar Antonio DF, Alcaraz-Fuerte C, García Baysa M, López Jiménez JL, Márquez-Guillén E, Vilatobá M, Cruz-Martínez R, Carpinteyro-Espin P, Chávez-Villa M, Romero Morelos RD, Torres-Del Real D, Uscanga-Domínguez LF, García-Alanis M, Tapia Sosa R, Servín-Rojas M, Valdez-Echeverria RD, García-Juárez I. Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients. Vaccine 2022:S0264-410X(22)01012-X. [PMID: 36028456 DOI: 10.1016/j.vaccine.2022.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, Ho A, Aston S, Wootton DG, Richter A, de Silva TI, Hardwick HE, Leeming G, Law A, Openshaw PJ, Harrison EM, Baillie JK, Semple MG, Docherty AB, ISARIC4C investigators. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study.. [DOI: 10.1101/2022.08.08.22278576] [Reference Citation Analysis]
33 Joseph A, Lafarge A, Mabrouki A, Abdel-Nabey M, Binois Y, Younan R, Azoulay E. Severe infections in recipients of cancer immunotherapy: what intensivists need to know. Curr Opin Crit Care 2022. [PMID: 35950720 DOI: 10.1097/MCC.0000000000000978] [Reference Citation Analysis]
34 Jongkees MJ, Geers D, Hensley KS, Huisman W, Geurtsvankessel CH, Bogers S, Gommers L, Papageorgiou G, Jochems SP, den Hollander JG, Schippers EF, Ammerlaan HS, Bierman WF, van der Valk M, Berrevoets MA, Soetekouw R, Langebeek N, Bruns AH, Leyten EM, Sigaloff KC, van Vonderen MG, Delsing CE, Branger J, Katsikis PD, Mueller YM, de Vries RD, Rijnders BJ, Brinkman K, Rokx C, Roukens AH. Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people living with HIV with hyporesponse after primary vaccination.. [DOI: 10.1101/2022.08.10.22278577] [Reference Citation Analysis]
35 Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, Golinski M, Hausinger RI, Mellinghoff S, Lange B, Lischetzki T, Kappler V, Mikolajewska A, Monsef I, Park YS, Piechotta V, Schmaderer C, Stegemann M, Vanshylla K, Weber F, Weibel S, Stephani C, Skoetz N. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Thompson MA, Hallmeyer S, Fitzpatrick VE, Liao Y, Mullane MP, Medlin SC, Copeland K, Weese JL. Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies. J Patient Cent Res Rev 2022;9:149-57. [PMID: 35935520 DOI: 10.17294/2330-0698.1952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Müller L, Andrée M, Moskorz W, Drexler I, Hauka S, Ptok J, Walotka L, Grothmann R, Hillebrandt J, Ritchie A, Peter L, Walker A, Timm J, Adams O, Schaal H. Adjusted booster schedules disperse age-dependent differences in antibody titers benefitting risk populations.. [DOI: 10.1101/2022.08.08.22278545] [Reference Citation Analysis]
38 Rinaldi I, Pratama S, Wiyono L, Tandaju JR, Wardhana IL, Winston K. Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis. Front Oncol 2022;12:951215. [DOI: 10.3389/fonc.2022.951215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 The OpenSAFELY Collaborative, Nab L, Parker EP, Andrews CD, Hulme WJ, Fisher L, Morley J, Mehrkar A, Mackenna B, Inglesby P, Morton CE, Bacon SC, Hickman G, Evans D, Ward T, Smith RM, Davey S, Dillingham I, Maude S, Butler-cole BF, O’dwyer T, Stables CL, Bridges L, Bates C, Cockburn J, Parry J, Hester F, Harper S, Zheng B, Williamson EJ, Eggo RM, Evans S, Goldacre B, Tomlinson LA, Walker AJ. Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England.. [DOI: 10.1101/2022.07.30.22278161] [Reference Citation Analysis]
40 Piccicacco N, Zeitler K, Ing A, Montero J, Faughn J, Silbert S, Kim K. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. J Antimicrob Chemother 2022:dkac256. [PMID: 35913836 DOI: 10.1093/jac/dkac256] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Hernández-Terán A, Garcíadiego-Fossas P, Villanueva-Reza M, Boukadida C, Taboada B, Porras E, Ahumada-Topete V, Tapia-Diaz KE, Matías-Florentino M, Pérez-García M, Ávila-Ríos S, Mejía-Nepomuceno F, Serna-Muñoz R, Juárez-Hernández F, Jiménez-Corona ME, Becerril-Vargas E, Barreto O, Martínez-Orozco JA, Pérez-Padilla R, Arias CF, Vázquez-Pérez JA. Clinical and Virological Features of Patients Hospitalized with Different Types of COVID-19 Vaccination in Mexico City. Vaccines (Basel) 2022;10:1181. [PMID: 35893830 DOI: 10.3390/vaccines10081181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kim WJ, Choi SH, Park JY, Song JS, Chung JW, Choi ST. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Ann Rheum Dis 2022:annrheumdis-2022-222689. [PMID: 35878999 DOI: 10.1136/ard-2022-222689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Hayer J, Urlaub E. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals. Microbiol Spectr 2022;10:e0270921. [PMID: 35575594 DOI: 10.1128/spectrum.02709-21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Li J, Ayada I, Wang Y, den Hoed CM, Kamar N, Peppelenbosch MP, de Vries AC, Li P, Pan Q. Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. Transplantation 2022. [PMID: 35761439 DOI: 10.1097/TP.0000000000004256] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 AlMutairi LT, Alalayet WY, Ata SI, Alenzi KA, AlRuthia Y. Self-Reported COVID-19 Vaccines' Side Effects among Patients Treated with Biological Therapies in Saudi Arabia: A Multicenter Cross-Sectional Study. Vaccines (Basel) 2022;10:977. [PMID: 35746586 DOI: 10.3390/vaccines10060977] [Reference Citation Analysis]
46 Sjöwall J, Hjorth M, Gustafsson A, Göransson R, Larsson M, Waller H, Nordgren J, Nilsdotter-Augustinsson Å, Nyström S. SARS-CoV-2 Specific Antibody Response and T Cell-Immunity in Immunocompromised Patients up to Six Months Post COVID: A Pilot Study. J Clin Med 2022;11:3535. [PMID: 35743605 DOI: 10.3390/jcm11123535] [Reference Citation Analysis]
47 Hendrickx R, Jellingsø M, Sommer MO. Kidney patients remain at increased risk for succumbing to COVID-19.. [DOI: 10.1101/2022.06.12.22276220] [Reference Citation Analysis]
48 Beale S, Burns R, Braithwaite I, Byrne T, Erica Fong WL, Fragaszy E, Geismar C, Hoskins S, Kovar J, Navaratnam AMD, Nguyen V, Patel P, Yavlinsky A, Van Tongeren M, Aldridge RW, Hayward A. Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study.. [DOI: 10.1101/2022.06.12.22276307] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Agurto-Arteaga A, Poma-Acevedo A, Rios-Matos D, Choque-Guevara R, Montesinos-Millán R, Montalván Á, Isasi-Rivas G, Cauna-Orocollo Y, Cauti-Mendoza MG, Pérez-Martínez N, Gutierrez-Manchay K, Ramirez-Ortiz I, Núñez-Fernández D, Salguedo-Bohorquez MI, Quiñones-Garcia S, Fernández Díaz M, Guevara Sarmiento LA, Zimic M; COVID-19 Working Group in Perú. Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19. Front Immunol 2022;13:881604. [PMID: 35664008 DOI: 10.3389/fimmu.2022.881604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
50 Greenan-barrett J, Ciurtin C. COVID-19 in Immunocompromised Children and Adolescents. Pediatric Infectious Disease Journal 2022;Publish Ahead of Print. [DOI: 10.1097/inf.0000000000003605] [Reference Citation Analysis]
51 Vong L, Roifman CM. COVID-19 outcomes in immunocompromised individuals: seroconversion and vaccine effectiveness. LymphoSign Journal 2022;9:33-39. [DOI: 10.14785/lymphosign-2022-0006] [Reference Citation Analysis]
52 Mehta P, Gasparyan AY, Zimba O, Kitas GD. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. Clin Rheumatol 2022. [PMID: 35639259 DOI: 10.1007/s10067-022-06227-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
53 Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ 2022;377:e069989. [PMID: 35640925 DOI: 10.1136/bmj-2022-069989] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
54 Napuri NI, Curcio D, Swerdlow DL, Srivastava A. Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. Infect Dis Ther 2022. [PMID: 35614299 DOI: 10.1007/s40121-022-00648-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Bhiman JN, Moore PL. Leveraging South African HIV research to define SARS‐CoV ‐2 immunity triggered by sequential variants of concern. Immunological Reviews. [DOI: 10.1111/imr.13086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Podrazil M, Taborska P, Stakheev D, Rataj M, Lastovicka J, Vlachova A, Pohunek P, Bartunkova J, Smrz D. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. Front Immunol 2022;13:892277. [DOI: 10.3389/fimmu.2022.892277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 See KC. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines 2022;10:800. [DOI: 10.3390/vaccines10050800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Netw Open 2022;5:e2210780. [PMID: 35532938 DOI: 10.1001/jamanetworkopen.2022.10780] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
59 Assawasaksakul T, Lertussavavivat T, Sathitratanacheewin S, Oudomying N, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Avihingsanon Y, Assawasaksakul N, Kittanamongkolchai W. Comparison of immunogenicity and safety of inactivated, adenovirus-vectored and heterologous adenovirus-vectored/mRNA vaccines in patients with systemic lupus erythematosus and rheumatoid arthritis: a prospective cohort study.. [DOI: 10.1101/2022.04.22.22274158] [Reference Citation Analysis]
60 Lee ARYB, Wong SY, Tay SH. Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety. Vaccines 2022;10:668. [DOI: 10.3390/vaccines10050668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Stadler E, Chai KL, Schlub TE, Cromer D, Polizzotto MN, Kent SJ, Beecher C, White H, Turner T, Skoetz N, Estcourt L, Mcquilten ZK, Wood EM, Khoury DS, Davenport MP. Determinants of passive antibody efficacy in SARS-CoV-2 infection.. [DOI: 10.1101/2022.03.21.22272672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
62 Avagyan S, Zilfyan A, Muradyan A. New approaches related to the use of polyamine-free and polyamine-deficient diets in the list of nutritional products for COVID-19 patients. NAMJ 2022. [DOI: 10.56936/18290825-2022.16.2-14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Hayer J, Urlaub E. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in samples from vaccinated individuals.. [DOI: 10.1101/2021.12.17.21267927] [Reference Citation Analysis]